History of injection drug use in the month preceding incarceration in Iranian prisons
Abstract This study aimed to investigate the prevalence and pattern of injecting drug use (IDU) in Iranian incarcerated people one month before their imprisonment. This cross-sectional study used data from the national Bio-Behavioral Surveillance Surveys conducted from a random sample of people inca...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-05-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-02537-3 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850269291314675712 |
|---|---|
| author | Mitra Darbandi Willi McFarland Soheil Mehmandoost Fatemeh Tavakoli Maliheh Sadat Bazrafshan Naser Nasiri Ali Akbar Haghdoost Meraj Sharifi Roya Safari Faramani Hamid Sharifi |
| author_facet | Mitra Darbandi Willi McFarland Soheil Mehmandoost Fatemeh Tavakoli Maliheh Sadat Bazrafshan Naser Nasiri Ali Akbar Haghdoost Meraj Sharifi Roya Safari Faramani Hamid Sharifi |
| author_sort | Mitra Darbandi |
| collection | DOAJ |
| description | Abstract This study aimed to investigate the prevalence and pattern of injecting drug use (IDU) in Iranian incarcerated people one month before their imprisonment. This cross-sectional study used data from the national Bio-Behavioral Surveillance Surveys conducted from a random sample of people incarcerated in 33 prisons covering the major geographical areas of Iran in 2017 (n = 5,785). A multivariable logistic regression model was used to determine factors related to IDU one month before imprisonment. The lifetime prevalence of IDU among Iranian incarcerated people was 12.2% (95% confidence interval [CI] 11.4, 13.1), of whom 19.2% (95% CI16.3, 22.3) injected in the month before imprisonment. Among incarcerated people with a lifetime history of IDU, the average age at which they started IDU was 24.5 ± 5.9 years, and the mean injection duration was 36.8 months (95% CI 33.5, 40.1). Friends were the initial influence for starting IDU in 67.7% of cases. Additionally, 58.6% of incarcerated people with a history of IDU used a new syringe/needle for injections in the month before imprisonment. Participants over 40 years old were less likely to inject in the month before incarceration than the 18-to-29-year age group (adjusted odds ratio [AOR] 0.37, 95% CI 0.19, 0.73). A history of previous imprisonment (AOR 2.17, 95% CI 1.27, 3.70) and having a tattoo (AOR 1.75, 95% CI 1.15, 2.68) showed significant positive associations with IDU in the month before imprisonment. The study found that one in eight persons detained in Iran had a history of IDU, of whom one in five injected in the month before incarceration with higher rates among persons with younger age, tattoos, and previous incarceration. Implementing targeted prevention programs within prisons, including better access to rehabilitation and needle exchange programs, is recommended to reduce the risks of infectious disease transmission including HIV and HCV. |
| format | Article |
| id | doaj-art-25c71abe339f42fa8df589a3f89b5d97 |
| institution | OA Journals |
| issn | 2045-2322 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-25c71abe339f42fa8df589a3f89b5d972025-08-20T01:53:11ZengNature PortfolioScientific Reports2045-23222025-05-011511710.1038/s41598-025-02537-3History of injection drug use in the month preceding incarceration in Iranian prisonsMitra Darbandi0Willi McFarland1Soheil Mehmandoost2Fatemeh Tavakoli3Maliheh Sadat Bazrafshan4Naser Nasiri5Ali Akbar Haghdoost6Meraj Sharifi7Roya Safari Faramani8Hamid Sharifi9Student Research Committee, Kermanshah University of Medical SciencesDepartment of Epidemiology and Biostatistics, University of California San FranciscoHIV/STI Surveillance Research Center, WHO Collaborating Center for HIV Surveillance, Institute for Futures Studies in Health, Kerman University of Medical SciencesHIV/STI Surveillance Research Center, WHO Collaborating Center for HIV Surveillance, Institute for Futures Studies in Health, Kerman University of Medical SciencesHIV/STI Surveillance Research Center, WHO Collaborating Center for HIV Surveillance, Institute for Futures Studies in Health, Kerman University of Medical SciencesHIV/STI Surveillance Research Center, WHO Collaborating Center for HIV Surveillance, Institute for Futures Studies in Health, Kerman University of Medical SciencesHIV/STI Surveillance Research Center, WHO Collaborating Center for HIV Surveillance, Institute for Futures Studies in Health, Kerman University of Medical SciencesStudent Research Committee, Kerman University of Medical SciencesSocial Development and Health Promotion Research Center, Research Institute for Health, Kermanshah University of Medical SciencesHIV/STI Surveillance Research Center, WHO Collaborating Center for HIV Surveillance, Institute for Futures Studies in Health, Kerman University of Medical SciencesAbstract This study aimed to investigate the prevalence and pattern of injecting drug use (IDU) in Iranian incarcerated people one month before their imprisonment. This cross-sectional study used data from the national Bio-Behavioral Surveillance Surveys conducted from a random sample of people incarcerated in 33 prisons covering the major geographical areas of Iran in 2017 (n = 5,785). A multivariable logistic regression model was used to determine factors related to IDU one month before imprisonment. The lifetime prevalence of IDU among Iranian incarcerated people was 12.2% (95% confidence interval [CI] 11.4, 13.1), of whom 19.2% (95% CI16.3, 22.3) injected in the month before imprisonment. Among incarcerated people with a lifetime history of IDU, the average age at which they started IDU was 24.5 ± 5.9 years, and the mean injection duration was 36.8 months (95% CI 33.5, 40.1). Friends were the initial influence for starting IDU in 67.7% of cases. Additionally, 58.6% of incarcerated people with a history of IDU used a new syringe/needle for injections in the month before imprisonment. Participants over 40 years old were less likely to inject in the month before incarceration than the 18-to-29-year age group (adjusted odds ratio [AOR] 0.37, 95% CI 0.19, 0.73). A history of previous imprisonment (AOR 2.17, 95% CI 1.27, 3.70) and having a tattoo (AOR 1.75, 95% CI 1.15, 2.68) showed significant positive associations with IDU in the month before imprisonment. The study found that one in eight persons detained in Iran had a history of IDU, of whom one in five injected in the month before incarceration with higher rates among persons with younger age, tattoos, and previous incarceration. Implementing targeted prevention programs within prisons, including better access to rehabilitation and needle exchange programs, is recommended to reduce the risks of infectious disease transmission including HIV and HCV.https://doi.org/10.1038/s41598-025-02537-3Injecting drug useImprisonmentIran |
| spellingShingle | Mitra Darbandi Willi McFarland Soheil Mehmandoost Fatemeh Tavakoli Maliheh Sadat Bazrafshan Naser Nasiri Ali Akbar Haghdoost Meraj Sharifi Roya Safari Faramani Hamid Sharifi History of injection drug use in the month preceding incarceration in Iranian prisons Scientific Reports Injecting drug use Imprisonment Iran |
| title | History of injection drug use in the month preceding incarceration in Iranian prisons |
| title_full | History of injection drug use in the month preceding incarceration in Iranian prisons |
| title_fullStr | History of injection drug use in the month preceding incarceration in Iranian prisons |
| title_full_unstemmed | History of injection drug use in the month preceding incarceration in Iranian prisons |
| title_short | History of injection drug use in the month preceding incarceration in Iranian prisons |
| title_sort | history of injection drug use in the month preceding incarceration in iranian prisons |
| topic | Injecting drug use Imprisonment Iran |
| url | https://doi.org/10.1038/s41598-025-02537-3 |
| work_keys_str_mv | AT mitradarbandi historyofinjectiondruguseinthemonthprecedingincarcerationiniranianprisons AT willimcfarland historyofinjectiondruguseinthemonthprecedingincarcerationiniranianprisons AT soheilmehmandoost historyofinjectiondruguseinthemonthprecedingincarcerationiniranianprisons AT fatemehtavakoli historyofinjectiondruguseinthemonthprecedingincarcerationiniranianprisons AT malihehsadatbazrafshan historyofinjectiondruguseinthemonthprecedingincarcerationiniranianprisons AT nasernasiri historyofinjectiondruguseinthemonthprecedingincarcerationiniranianprisons AT aliakbarhaghdoost historyofinjectiondruguseinthemonthprecedingincarcerationiniranianprisons AT merajsharifi historyofinjectiondruguseinthemonthprecedingincarcerationiniranianprisons AT royasafarifaramani historyofinjectiondruguseinthemonthprecedingincarcerationiniranianprisons AT hamidsharifi historyofinjectiondruguseinthemonthprecedingincarcerationiniranianprisons |